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Objective. Classiﬁcation criteria for systemic sclerosis (SSc; scleroderma) are being updated jointly by the American
College of Rheumatology and European League Against Rheumatism. Potential items for classiﬁcation were reduced to 23
using Delphi and nominal group techniques. We evaluated the face, discriminant, and construct validity of the items to
be further studied as potential criteria.
Methods. Face validity was evaluated using the frequency of items in patients sampled from the Canadian Scleroderma
Research Group, 1000 Faces of Lupus, and the Pittsburgh, Toronto, Madrid, and Berlin connective tissue disease (CTD)
databases. Patients with SSc (n 783) were compared to 1,071 patients with diseases similar to SSc (mimickers): systemic
lupus erythematosus (n  499), myositis (n  171), Sjo¨gren’s syndrome (n  95), Raynaud’s phenomenon (RP; n  228),
mixed CTD (n 29), and idiopathic pulmonary arterial hypertension (PAH; n 49). Discriminant validity was evaluated
using odds ratios (ORs). For construct validity, empirical ranking was compared to expert ranking.
Results. Compared to mimickers, patients with SSc were more likely to have skin thickening (OR 427); telangiectasias
(OR 91); anti–RNA polymerase III antibody (OR 75); puffy ﬁngers (OR 35); ﬁnger ﬂexion contractures (OR 29); tendon/
bursal friction rubs (OR 27); anti–topoisomerase I antibody (OR 25); RP (OR 24); ﬁngertip ulcers/pitting scars (OR 19);
anticentromere antibody (OR 14); abnormal nailfold capillaries (OR 10); gastroesophageal reﬂux disease symptoms (OR
8); antinuclear antibody, calcinosis, dysphagia, and esophageal dilation (all OR 6); interstitial lung disease/pulmonary
ﬁbrosis (OR 5); and anti–PM-Scl antibody (OR 2). Reduced carbon monoxide diffusing capacity, PAH, and reduced forced
vital capacity had ORs of <2. Renal crisis and digital pulp loss/acroosteolysis did not occur in SSc mimickers (OR not
estimated). Empirical and expert ranking were correlated (Spearman’s   0.53, P  0.01).
Conclusion. The candidate items have good face, discriminant, and construct validity. Further item reduction will be
evaluated in prospective SSc and mimicker cases.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a heterogeneous
disease or possibly a family of closely related diseases
characterized by vasculopathy, immune activation, and
ﬁbrosis. Its clinical manifestations vary across individuals,
resulting in differences in organ system involvement,
treatment regimens, and prognosis. In the absence of a
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diagnostic test for SSc, several sets of classiﬁcation criteria
have been developed and used to identify patients with
similar features for recruitment into clinical studies (1–4).
The use of classiﬁcation criteria as inclusion criteria for
study participation has facilitated comparison of results
across studies.
Existing classiﬁcation criteria for SSc should be updated
(5–10). With improved understanding of the disease, the
items regarded to be important for SSc have increased
(5,11,12). Goetz and Berne were among the ﬁrst to describe
gastrointestinal involvement in SSc, yet they did not in-
corporate this domain in their criteria (13). It has also been
recognized that use of the 1980 American College of Rheu-
matology (ACR) preliminary criteria (1–3) for recruitment
into clinical trials results in the exclusion of up to 20% of
patients with either early SSc or the limited cutaneous
subtype of SSc (8,9,14). The exclusion of the limited cu-
taneous SSc patients is likely due to the fact that a dispro-
portionate number of diffuse cutaneous SSc patients were
entered into the ACR prospective study. Therefore, the
statistical analysis resulted in criteria that identiﬁed 100%
of diffuse cutaneous SSc patients, but only 80% of limited
cutaneous SSc patients. It has been demonstrated recently
that the addition of nailfold capillary abnormalities and
telangiectasias to the ACR SSc criteria improves their sen-
sitivity (6,8).
Few criteria sets were developed for wide-scale applica-
tion in classifying patients for clinical research studies
(15,16). Most criteria sets were developed for use in the
clinic or a study at hand, limiting their generalizability
(17,18). Standards for devising classiﬁcation criteria have
evolved since the original criteria sets were proposed (19).
The methodologies used to develop previous criteria do
not meet current standards (20,21). For example, one pre-
vious SSc criteria proposal utilized healthy subjects and
rheumatoid arthritis patients as the comparator groups (2).
It has been argued that these patients are so different that
they can nearly always be differentiated from SSc patients
(7). In keeping with the differential diagnosis faced by
clinicians in practice, it has been suggested that criteria
should be tested against control populations selected be-
cause they have SSc-like features (7). Examples include
other connective tissue diseases (CTDs), i.e., mixed CTD
(MCTD), Sjo¨gren’s syndrome, systemic lupus erythem-
atosus (SLE), polymyositis/dermatomyositis, and undiffer-
entiated CTD, other ﬁbrosing syndromes (eosinophilic
fasciitis, linear scleroderma, generalized morphea, sclero-
myxedema, nephrogenic systemic ﬁbrosis), and Raynaud’s
disease.
The Subcommittee on Classiﬁcation and Response Cri-
teria, a subcommittee of the ACR Quality of Care Commit-
tee, has published recommendations for the development
and validation of new criteria sets based on the current
standards of measurement science (19–21) that are com-
plemented by recommendations from the European
League Against Rheumatism (EULAR) Standing Commit-
tees of Clinical Epidemiology and for International Studies
Including Clinical Trials (22,23). Recommendations for
modern criteria development include 1) collaboration be-
tween clinical experts and clinical epidemiologists in cri-
teria development, 2) evaluation of the psychometric prop-
erties of each candidate criterion, and 3) description of the
derivation sample (origin of the patients and control sub-
jects) and gold standard (21–23). Ideally, phases of criteria
development should have a balance between expert opin-
ion and data-driven methods (21). Yet there should be
avoidance of circularity of reasoning (a bias that can occur
when the same experts developing the criteria are the ones
contributing cases and comparison patients) (19). A joint
international collaborative initiative supported by the
ACR and EULAR is underway to develop revised classiﬁ-
cation criteria for SSc where the methodology has consid-
ered these issues.
During phase 1 of the development process, potential
items for revised SSc classiﬁcation criteria were generated
through 2 independent international consensus exercises
performed by the Scleroderma Clinical Trials Consortium
and the EULAR Scleroderma Trials and Research group,
resulting in a list of 168 potential items (24). A Delphi
exercise of 105 international SSc experts reduced the list
of potential items to 102 items. The item list was again
rated and subjected to a consensus meeting using nominal
group technique by a separate group of European and
North American SSc experts, further reducing the list to 23
items (24). As recommended, the next phase of SSc criteria
development requires evaluation of the psychometric
properties of each candidate criterion (21,23). An impor-
tant psychometric property of criteria is their validity, the
degree to which their application corresponds to the truth.
In this study we aimed to evaluate the validity of candi-
date items for revised SSc criteria. In particular, the objec-
tive of this study was to evaluate the face, discriminant,
and construct validity of the candidate items. This knowl-
edge will inform the subsequent phases of SSc criteria
development.
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Signiﬁcance & Innovations
● The candidate items for systemic sclerosis classi-
ﬁcation criteria have good face, discriminant, and
construct validity.
● This study, a joint collaboration between the
American College of Rheumatology and the Euro-
pean League Against Rheumatism, involved a
large number of connective tissue disease patients
that were recruited from multiple sites in North
America and Europe.
● The results justify proceeding with the next phase
of criteria development, which is prospective case
and control ascertainment.
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SUBJECTS AND METHODS
SSc patients and comparison subjects. SSc patients
were identiﬁed from established longitudinal cohorts that
were not developed for the purpose of this study. Item
deﬁnitions were often cohort speciﬁc and not necessarily
identical between cohorts. Representatives of cohorts were
invited to participate in this study based on geographic
representation (North America and Europe), size, use of
standardized data collection in both SSc and comparison
patients, and willingness to participate. Comparison pa-
tients represented a spectrum of rheumatic and nonrheu-
matic diseases that share clinical manifestations with SSc.
Patients with SSc that overlapped with another rheumatic
disease were not included. In all cohorts, the diagnoses
were based on the local center’s physician(s) judgment.
Only a subset of each cohort was sampled (10% randomly
selected from each database with the exception of the
Pittsburgh cohort, which was sampled by year) for this
study, leaving the remainder available for future valida-
tion studies.
The Canadian Scleroderma Research Group (CSRG) da-
tabase patients were compared with the 1000 Faces of
Lupus database patients. Both are Canadian multicenter
cohorts that recruit patients from academic and commu-
nity settings. The University of Pittsburgh Connective Tis-
sue Disease Database, the Toronto Scleroderma Database
and the Toronto Pulmonary Hypertension in the Connec-
tive Tissue Diseases Database, the Madrid Scleroderma
cohort, and the Berlin Scleroderma cohort are single-cen-
ter, academic hospital–based cohorts. SSc patients were
compared to the patients who did not have SSc but had a
disease similar to SSc (non-SSc comparisons) within each
database. In the case of the CSRG patients and the 1000
Faces of Lupus patients, the items of interest were com-
pared between the databases, where available.
Candidate items. The 23 candidate items were: anti–
topoisomerase I antibody; scleroderma (skin thickening on
examination); abnormal nailfold capillary pattern; anti-
centromere antibody or centromere pattern on antinuclear
antibody (ANA) test; anti–RNA polymerase III antibody;
ﬁngertip and/or periungal ulcers or pitting scars; Ray-
naud’s phenomenon; interstitial lung disease or pulmo-
Table 1. Frequency of positive responses and ORs for candidate items in the CSRG and 1000 Faces of
Lupus cohorts*
Criterion
Scleroderma
(n  127)
SLE
(n  127) OR†
Abnormal nailfold capillary pattern 93/126 (74) NA NA
Anticentromere antibody 32/109 (29) 1/126 (0.8) 52
Anti–topoisomerase I antibody 18/103 (17) 1/127 (0.8) 27
Antinuclear antibody 101/109 (93) 125/127 (98) 0.2
Anti–PM-Scl antibody 9/80 (11) NA NA
Anti–RNA polymerase III antibody 15/83 (18) NA NA
Calcinosis 43/125 (34) NA NA
Reduced DLCO‡ 51/106 (48) NA NA
Digital pulp loss or acroosteolysis 55/124 (44) 0/127 (0) NE
Dysphagia for solids 74/116 (64) NA NA
Esophageal dilation 14/125 (11) NA NA
Finger ﬂexion contractures 37/127 (29) NA NA
Fingertip ulcers or pitting scars 76/126 (60) 2/126 (2) 94
Reduced FVC‡ 8/90 (9) NA NA
ILD or pulmonary ﬁbrosis§ 44/122 (36) 1/125 (0.8) 66
Gastroesophageal reﬂux disease¶ 106/126 (84) NA NA
Puffy ﬁngers 65/125 (52) NA NA
Pulmonary arterial hypertension# 8/107 (7) 3/124 (2) 3
Raynaud’s phenomenon 123/127 (97) 56/127 (44) 39
Renal crisis 6/126 (5) NA NA
Scleroderma skin changes 118/124 (95) NA NA
Telangiectasias 90/119 (76) 0/127 (0) NE
Tendon or bursal friction rubs 18/125 (14) NA NA
* Values are the number/total (percentage) unless otherwise indicated. OR  odds ratio; CSRG  Canadian Scleroderma
Research Group; SLE  systemic lupus erythematosus; NA  not available; DLCO  carbon monoxide diffusing capacity; NE 
not estimated; FVC  forced vital capacity; ILD  interstitial lung disease.
† Can be read as systemic sclerosis patients have OR times the odds of having candidate criteria than a mimicker patient.
‡ 70% predicted.
§ ILD (CSRG data) was considered present if a high-resolution computed tomography (HRCT) lung was interpreted by an
experienced radiologist as showing ILD or, in the case where no HRCT was performed, if either a chest radiograph was reported
as showing either increased interstitial markings (not thought to be due to congestive heart failure) or ﬁbrosis and/or if a study
physician reported ﬁndings indicative of ILD on physical examination.
¶ Gastroesophageal reﬂux disease was deﬁned as the patient having reported a history of heartburn, regurgitation of acid, and/or
nocturnal choking, and/or ever taking gastroprotective agents.
# Pulmonary hypertension was deﬁned as an estimated pulmonary artery systolic pressure of 45 mm Hg (CSRG data).
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nary ﬁbrosis; renal crisis; reduced carbon monoxide dif-
fusing capacity (DLCO); reduced forced vital capacity
(FVC); dysphagia for solid food by history; esophageal
dilation on radiograph, barium swallow, or high-resolu-
tion computerized tomography; telangiectasias; ﬁnger ﬂex-
ion contractures; ANA; anti–PM-Scl antibody; pulmonary
arterial hypertension; puffy ﬁngers; digital pulp loss or
acroosteolysis; persistent recurrent gastroesophageal re-
ﬂux disease by history; calcinosis; and tendon or bursal
friction rubs (24). All of the items were deﬁned using the
local research protocols and harmonized across the data-
bases, where possible. For example, DLCO and FVC abnor-
malities were deﬁned as either 70% or 80% predicted,
depending on the cohort. The same deﬁnitions were ap-
plied for within-group comparisons. These deﬁnitions can
be found in the footnotes accompanying each table. Serol-
ogies were identiﬁed based on local laboratory assays. The
response for each candidate item was dichotomized as
present or absent.
Validity. Face validity is present if the items measure
what they purport to measure (25,26). Typically, this is
assessed using expert judgment, but should be comple-
mented by data-driven methods (26). Face validity was
evaluated using the occurrence of positive responses to
each item in patients with SSc. For items with a dichoto-
mous response, this is the proportion of patients who gave
a positive response (having the item in question) (26). It is
suggested that items with positive rates of 20% may be
eliminated (26). When the majority of patients do not have
the item, very little is gained by retaining the item in a
criteria set. The item may not improve the psychometric
properties of the criteria set and may actually detract from
it by making it longer (26). However, a low frequency item
may still be retained if it confers other beneﬁcial proper-
ties. For example, a low frequency item may differentiate
SSc patients from mimicking conditions very well.
Discriminative validity of each item was evaluated using
SSc patients and patients with a disease similar to SSc
Table 2. Frequency of positive responses and ORs for candidate items in the University of Pittsburgh Connective Tissue
Disease cohort*
Criterion
Scleroderma
(n  326)
Non-SSc comparisons
Combined non-SSc
comparisons OR†
SLE
(n  113)
PM/DM
(n  118)
SS
(n  95)
Raynaud’s
disease
Abnormal nailfold capillary pattern 18/26 (69) NA 21/42 (50) 3/5 (60) 20/36 (56) 44/83 (53) 2
Anticentromere antibody 95/313 (30) 2/110 (2) 1/82 (1) 2/51 (4) 11/84 (13) 16/327 (5) 8
Anti–topoisomerase I antibody 63/313 (20) NA 0/82 (0) 0/51 (0) 4/84 (5) 4/217 (2) 18
Antinuclear antibody 298/313 (95) 64/72 (89) 60/82 (74) 35/51 (69) 63/84 (75) 222/289 (77) 6
Anti–PM-Scl antibody 9/313 (3) NA 2/82 (2) 0/51 (0) 1/84 (1) 3/217 (2) 2
Anti–RNA polymerase III antibody 81/313 (26) NA 1/82 (1) 0/51 (0) 0/84 (0) 1/217 (0.5) 75
Calcinosis 35/241 (15) NA 6/75 (8) 1/15 (7) 0/36 (0) 7/126 (6) 3
Reduced DLCO‡ 118/190 (62) 2/7 (29) 44/59 (75) 2/11 (18) 6/14 (43) 54/91 (59) 1
Digital pulp loss or acroosteolysis§ 12/125 (10) NA 0/18 (0) 0/11 (0) 0/9 (0) 0/38 (0) NC
Dysphagia for solids 139/325 (43) 6/106 (6) 23/117 (20) 15/95 (16) 14/93 (15) 58/411 (14) 10
Esophageal dilation¶ 106/163 (65) NA 5/19 (26) 6/25 (24) 6/23 (26) 17/67 (25) 5
Finger ﬂexion contracture 203/324 (63) 8/112 (7) 5/117 (4) 7/95 (7) 3/92 (3) 23/416 (6) 29
Fingertip ulcers or pitting scars 149/324 (46) 4/107 (4) 2/116 (2) 1/95 (1) 12/92 (13) 19/410 (5) 18
Reduced FVC‡ 61/204 (30) NA 25/62 (40) 0/12 (0) 3/15 (20) 28/89 (31) 0.9
ILD or pulmonary ﬁbrosis# 106/259 (41) 1/50 (2) 40/71 (56) 4/46 (9) 2/30 (7) 47/197 (24) 2
Gastroesophageal reﬂux disease** 234/325 (72) 28/106 (26) 39/117 (33) 30/95 (32) 37/93 (40) 134/411 (33) 16
Puffy ﬁngers 285/325 (88) 14/111 (13) 12/117 (10) 8/95 (8) 13/92 (14) 47/415 (11) 56
Pulmonary arterial hypertension†† 28/326 (9) 3/113 (3) 2/118 (2) 0/95 (0) 1/93 (1) 6/419 (1) 6
Raynaud’s phenomenon 318/326 (98) 67/113 (59) 44/117 (38) 42/95 (44) 93/93 (100) 246/418 (59) 47
Renal crisis 22/326 (7) 0/113 (0) 0/118 (0) 0/95 (0) 0/93 (0) 0/419 (0) NA
Scleroderma 314/326 (96) 1/93 (1) 7/109 (6) 0/92 (0) 0/92 (0) 8/386 (2) 1,190
Telangiectasias‡‡ 180/325 (55) 2/107 (2) 1/115 (1) 8/95 (8) 2/92 (2) 13/409 (3) 38
Tendon or bursal friction rubs§§ 95/323 (29) 0/75 (0) 0/111 (0) 1/91 (1) 0/90 (0) 1/367 (0.3) 153
* Values are the number/total (percentage) unless otherwise indicated. OR odds ratio; SSc systemic sclerosis (scleroderma); SLE systemic lupus
erythematosus; PM/DM  polymyositis/dermatomyositis; SS  Sjo¨gren’s syndrome; NA  not available; DLCO  carbon monoxide diffusing capacity;
NC  not calculable; FVC  forced vital capacity; ILD  interstitial lung disease.
† Can be read as SSc patients have OR times the odds of having candidate criteria than a mimicker patient.
‡ 70% predicted.
§ Acroosteolysis on physical examination or radiographically.
¶ Esophageal dysmotility by barium swallow or manometry.
# Pulmonary ﬁbrosis radiographically.
** Heartburn by history.
†† Pulmonary arterial hypertension by clinical features (physical examination, echocardiogram) or right heart catheterization.
‡‡ Telangiectasias at any site that is believed to be due to connective tissue disease ﬁnger contractures recorded by the examining physician on
physical examination.
§§ One or more rubs, including the following sites: shoulders, olecranon bursae, wrists (ﬂexor or extensors), ﬁngers (ﬂexor or extensor), knees, and
ankles (Achilles, peroneal, posterior tibial, or anterior tibial tendons).
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(non-SSc comparison patients) from the same center. Us-
ing the positive rates, the odds ratio (OR) for each item was
calculated for each cohort separately and aggregated into a
pooled OR. The candidate items were ranked from highest
to lowest based on the pooled OR. It has been recom-
mended that items with an OR 2 be eliminated (27). In
the setting of classiﬁcation, ORs 2 provide better accu-
racy (27).
Construct validity evaluates the relationship of the item
to other measures that are believed to be part of the same
phenomenon or “construct” (28). In this study, construct
validity was assessed using the strength of association
between the empirical ranking based on the pooled OR
and the ranking based on expert judgment from a previous
Delphi exercise (24).
Statistical analysis. Summary statistics were used to
describe the data. ORs were calculated to analyze the
association between each item with case or comparison
status for each cohort separately. Bayesian statistics were
used to calculate the pooled mean OR and 95% credible
interval (95% CrI). This approach was taken because it
provides the reader the interval for which there is a 95%
probability that the true OR falls within (29). The Bayesian
analyses used an uninformative normal prior distribution
with a mean of 0 and a variance of 10,000 and Markov
chain Monte Carlo to sample from the posterior distribu-
tion of the items. Starting at 3 randomly generated initial
values, the chains were run for a 5,000 iteration “burn-in”
period where the chain moved from the starting value
toward the correct posterior distribution. The Brooks-
Gelman-Rubin statistic was used to verify convergence at
this point, i.e., that all 3 chains were sampling from the
same distribution. Then 10,000 new sampled values were
collected and used to estimate the properties of the poste-
rior distribution, i.e., the OR and 95% CrI. Reporting of the
analysis and results is in accordance with the ROBUST
criteria (30). The code for analyses is available from the
corresponding author upon request. The strength of asso-
ciation between the empirical ranking based on the pooled
OR and the ranking based on expert judgment was ana-
lyzed using the Spearman’s rho rank correlation coefﬁ-
cient. Given variation between experts in their rankings
and variation in measurement of criteria across cohorts,
we hypothesized a priori that a “moderate” correlation
(  0.4–0.6) between the 2 rankings would be signiﬁcant.
Analyses were performed using R (version 2.2.1, The R
Foundation for Statistical Computing) and WinBUGS (ver-
sion 1.4.3, Imperial College and Medical Research Coun-
cil).
Table 3. Frequency of positive responses and ORs for candidate items in the Toronto cohorts*
Criterion
Scleroderma
(n  86)
Non-SSc comparisons
Combined
non-SSc comparisons
(n  114), % OR†
SLE
(n  36)
MCTD
(n  29)
IPAH
(n  49)
Abnormal nailfold capillary pattern‡ 31 (36) 0 (0) 4 (14) 0 (0) 4 16
Anticentromere antibody 14 (16) 0 (0) 4 (14) 0 (0) 4 5
Anti–topoisomerase I antibody 15 (17) 1 (3) 0 (0) 0 (0) 0.9 24
Antinuclear antibody NA NA NA NA NA NA
Anti–PM-Scl antibody NA NA NA NA NA NA
Anti–RNA polymerase III antibody NA NA NA NA NA NA
Calcinosis 23 (27) 0 (0) 3 (10) 0 (0) 3 14
Reduced DLCO§ 30 (35) 13 (36) 15 (52) 17 (35) 39 0.8
Digital pulp loss or acroosteolysis NA NA NA NA NA NA
Dysphagia or gastroesophageal reﬂux disease 71 (83) 4 (11) 20 (69) 0 (0) 21 18
Esophageal dilation NA NA NA NA NA NA
Finger ﬂexion contractures NA NA NA NA NA NA
Fingertip ulcers or pitting scars 28 (33) 1 (3) 7 (24) 0 (0) 7 6
Reduced FVC§ 11 (13) 5 (14) 8 (28) 4 (8) 15 0.8
ILD or pulmonary ﬁbrosis 32 (37) 6 (17) 15 (52) 1 (2) 19 3
Gastroesophageal reﬂux disease NA NA NA NA NA NA
Puffy ﬁngers NA NA NA NA NA NA
Pulmonary arterial hypertension¶ 27 (31) 36 (100) 22 (76) 49 (100) 94 0.03
Raynaud’s phenomenon 83 (97) 15 (42) 26 (90) 3 (6) 39 44
Renal crisis 6 (7) 0 (0) 0 (0) 0 (0) 0 NE
Scleroderma 83 (97) 0 (0) 15 (52) 0 (0) 13 183
Telangiectasias 71 (83) 0 (0) 11 (38) 0 (0) 10 44
Tendon or bursal friction rubs NA NA NA NA NA NA
* Values are the number (percentage) unless otherwise indicated. OR  odds ratio; SSc  systemic sclerosis (scleroderma); SLE  systemic lupus
erythematosus; MCTD  mixed connective tissue disease; IPAH  idiopathic pulmonary arterial hypertension; NA  not available; DLCO  carbon
monoxide diffusing capacity; FVC  forced vital capacity; ILD  interstitial lung disease; NE  not estimated.
† Can be read as SSc patients have OR times the odds of having candidate criteria than a mimicker patient.
‡ Abnormal nailfold capillaries with enlargement or dropout by visual inspection or ophthalmoscope.
§ 70% predicted.
¶ Mimicker patients come from the pulmonary hypertension database, resulting in a high frequency of pulmonary hypertension within 1 cohort. The
results shown are therefore conservative.
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RESULTS
Patients and comparison subjects. Data on 783 SSc pa-
tients (CSRG n  127, Pittsburgh cohort n  326, Toronto
cohort n  86, Madrid cohort n  175, Berlin cohort n 
69) and 1,071 comparison subjects were evaluated in this
study. The comparison subjects included 499 SLE patients
(1000 Faces of Lupus cohort n  127, Pittsburgh cohort
n  113, Toronto cohort n  36, Madrid cohort n  223),
171 inﬂammatory myositis patients (Pittsburgh cohort n 
118, Madrid cohort n  53), 95 Sjo¨gren’s syndrome pa-
tients (Pittsburgh cohort), 228 Raynaud’s syndrome pa-
tients (Pittsburgh cohort n  93, Madrid cohort n  135),
29 MCTD patients (Toronto cohort), and 49 idiopathic
pulmonary arterial hypertension patients (Toronto cohort).
Face validity. Rates of positive responses for the candi-
date items in each SSc cohort are shown in Tables 1–5.
The presence of renal crisis and digital pulp loss or ac-
roosteolysis each occurred in 20% of all cohorts, where
measured. Anti–topoisomerase I antibody, anti–PM-Scl
antibody, calcinosis, reduced FVC, pulmonary arterial hy-
pertension, and ﬁnger ﬂexion contractures variably had
positive occurrence frequencies 20%, depending on the
cohort. The other candidate items were consistently posi-
tive in 20% of SSc patients.
Discriminant validity. The ORs for candidate items
comparing SSc to non-SSc comparison patients are shown
in Tables 1–4. The pooled mean ORs and 95% CrIs for the
candidate items are shown in Table 6. Pulmonary arterial
hypertension (OR 1.9, 95% CrI 1.4–2.4), reduced DLCO
(OR 1.5, 95% CrI 1.1–2.0), and reduced FVC (OR 0.9, 95%
CrI 0.6–1.3) had ORs 2. Renal crisis and digital pulp loss
or acroosteolysis did not occur in any of the non-SSc
comparison patients in any of the cohorts, and conse-
quently the ORs were not estimated. If an inﬁnitely small
numerical adjustment were added to facilitate estimation,
the result would be an inﬁnitely large OR.
Some of the Raynaud’s syndrome patients from the Pitts-
burgh cohort had the presence of ANAs, abnormal nailfold
capillaries, and positive serology, suggesting that they may
represent pre-SSc or pre–other CTDs. The pooled OR ana-
lysis was repeated excluding these patients, and there was
no substantial difference in the results.
Construct validity. The empirical-based and expert-
based rankings of the candidate criteria are shown in Table
Table 4. Frequency of positive responses and ORs for candidate items in the Madrid cohort*
Criterion
Scleroderma
(n  175)
Non-SSc comparisons
Combined non-SSc
comparisons
(n  411), no./total OR
SLE
(n  223)
Myositis
(n  53)†
Raynaud’s
disease
(n  135)
Abnormal nailfold capillary pattern 113/137 (83) NA NA 3/135 (2) 3/135 NA
Anticentromere antibody 45/167 (27) 3/203 (2) 1/53 (2) 1/135 (1) 5/391 28
Anti–topoisomerase I antibody 59/167 (35) 2/103 (2) 1/53 (2) 0/135 (0) 3/291 24
Antinuclear antibody 158/169 (94) 197/203 (97) 25/49 (51) 18/135 (13) 240/387 9
Anti–PM-Scl antibody NA NA NA NA NA NA
Anti–RNA polymerase III antibody NA NA NA NA NA NA
Calcinosis 10/56 (18) NA 5/53 (9) 0/135 (0) 5/188 8
Reduced DLCO‡ 55/93 (59) NA 12/38 (32) NA 12/38 3
Digital pulp loss or acroosteolysis 21/48 (44) NA NA NA NA NA
Dysphagia for solids NA NA 17/53 (32) NA 17/53 NA
Esophageal dilation NA NA NA NA NA NA
Finger ﬂexion contractures 23/123 (19) NA NA NA NA NA
Fingertip ulcers or pitting scars 77/173 (45) NA 6/53 (11) 3/135 (2) 9/188 16
Reduced FVC‡ 24/95 (25) NA 20/44 (46) NA 20/44 0.4
ILD or pulmonary ﬁbrosis 49/173 (28) 7/54 (13) 18/48 (38) 1/135 (1) 26/237 3
Gastroesophageal reﬂux disease 115/174 (66) NA 16/52 (31) 5/135 (4) 21/187 15
Puffy ﬁngers 73/124 (59) NA NA 9/135 (7) 9/135 20
Pulmonary arterial hypertension 36/170 (21) 3/223 (1) 2/52 (4) NA 5/275 14
Raynaud’s phenomenon 168/174 (97) 30/60 (50) 14/52 (27) 135/135 (100) 179/247 14
Renal crisis 13/174 (8) 0/223 (0) 0/53 (0) 0/135 (0) 0/411 NE
Scleroderma skin changes 154/175 (88) 2/200 (1) NA 4/135 (3) 6/335 402
Telangiectasias 31/65 (48) NA NA NA NA NA
Tendon or bursal friction rubs NA NA NA NA NA NA
* Values are the number/total (percentage) unless otherwise indicated. OR odds ratio; SSc systemic sclerosis (scleroderma); SLE systemic lupus
erythematosus; NA  not available; DLCO  carbon monoxide diffusing capacity; FVC  forced vital capacity; ILD  interstitial lung disease; NE 
not estimated.
† Patients with inﬂammatory myopathy fulﬁlling the criteria by Bohan and Peter (38,39), excluding those with overlap myopathy with SSc or SLE.
‡ 70% predicted.
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6. There was a moderate correlation between the 2 rank-
ings with a Spearman’s rho of 0.53 (P  0.01) (Figure 1).
DISCUSSION
Evaluation of the validity of candidate SSc items is an
important and necessary phase of classiﬁcation criteria
development. Our results demonstrate that the candidate
SSc items are valid: they have good face, discriminant, and
construct validity. Our study results also provide valuable
insights that should be considered in the subsequent
phases of criteria development that will include collecting
item frequencies on SSc and mimickers at multiple sites in
North America and Europe, using programs for item re-
duction, and then testing the validity of the ﬁnal criteria in
databases.
When there is face validity, motivation, cooperation,
and satisfaction among classiﬁcation criteria users in-
crease (26). The demonstration of face validity requires
more than peer judgments; empirical evidence is also re-
quired to show that a criterion is measuring what is in-
tended (26). In the case of SSc, this has an important
pragmatic implication. A proportion of SSc patients (ap-
proximately 20%) who have the disease have been ex-
cluded from participation in some clinical trials because
they do not meet existing classiﬁcation criteria. This is a
problem when a rare disease is being studied and a signif-
icant minority is excluded (6,9). It has been argued that
important domains of the disease have been left out of
previous criteria (such as antibodies and vascular compli-
cations). If the revised SSc classiﬁcation criteria incorpo-
rate items that improve the speciﬁcity of the criteria, then
more SSc patients can be included in studies from which
they may derive a beneﬁt. In this study, the majority of
candidate items have excellent face validity, with endorse-
ment frequencies of20%. Renal crisis, ﬁnger pulp loss or
acroosteolysis, anti–topoisomerase I antibody, anti–PM-
Scl antibody, calcinosis, reduced FVC, pulmonary arterial
hypertension, and ﬁnger ﬂexion contractures had lower
endorsement frequencies. The value of retaining these can-
didate criteria will need to be carefully evaluated in the
next phase of criteria development. It is uncertain if com-
bining uncommon features in revised SSc classiﬁcation
criteria would improve the sensitivity and/or speciﬁcity.
The utility of criteria with negative responses will also
need to be considered. There could be criteria where a
negative response makes SSc unlikely (such as absence of
ANA or Raynaud’s phenomenon). Furthermore, the value
of including criteria that rarely occur in SSc patients will
need to be balanced by the impact of including too many
criteria on the feasibility and reliability of the ﬁnal criteria
set. If a criterion is irrelevant, then users may omit it (26).
The majority of candidate criteria have excellent dis-
criminant validity with high pooled ORs. They effectively
discriminate patients with SSc from non-SSc comparison
patients included in this study. The utility of a few can-
didate criteria will require added scrutiny in the next
phase of criteria development. Renal crisis and digital
pulp loss or acroosteolysis occur uncommonly in SSc.
However, they had the strongest discriminating ability
because they never occurred in any of the non-SSc com-
parison patients in any of the cohorts. These criteria are
very good at discriminating patients with SSc from pa-
tients with other diseases. Criteria that are rare but unique
to SSc may be very speciﬁc for ruling in the disease, but do
not assist in the objective of being more inclusive of those
with the disease. Pulmonary arterial hypertension, re-
duced DLCO, and reduced FVC had ORs 2, indicating a
weak discriminating ability. The value of retaining these
items will need to be evaluated.
The candidate criteria also had good construct validity.
There was good agreement between the empirical-based
ranking and the expert-based ranking of the importance of
the candidate items. Both methods highlight those criteria
that should be considered very important and those that
can be considered less important in criteria set develop-
ment. In this case, the empirical data complement and
verify the expert-based data, indicating that criteria devel-
opment is evolving in the right direction.
This study has a number of strengths. First, our valida-
tion study has used large numbers of patients (for an
uncommon disease). It has been recommended that a sam-
ple size of at least 50 patients be used to evaluate the
frequency of an item (26). Other criteria sets have been
criticized for using inadequate numbers of patients and
controls (21,23). The comparator groups reﬂect other CTDs
and comparisons with nonrheumatic diseases and non-
rheumatology settings (21,23). Patients included in this
study were recruited from multiple sites in North America
and Europe. Previous SSc criteria development did not
Table 5. Frequency of positive responses for candidate
items in the Berlin cohort*
Criterion
Scleroderma
(n  69)
Abnormal nailfold capillary pattern NA
Anticentromere antibody 19 (28)
Anti–topoisomerase I antibody 15 (22)
Antinuclear antibody 63 (91)
Anti–PM-Scl antibody 3 (4)
Anti–RNA polymerase III antibody 4 (6)
Calcinosis NA
Reduced DLCO† 53 (77)
Digital pulp loss or acroosteolysis NA
Dysphagia for solids 47 (68)
Esophageal dilation NA
Finger ﬂexion contractures 32 (46)
Fingertip ulcers or pitting scars 22 (32)
Reduced FVC† 26 (38)
ILD or pulmonary ﬁbrosis 31 (45)
Gastroesophageal reﬂux disease 52 (75)
Puffy ﬁngers NA
Pulmonary arterial hypertension 25 (36)
Raynaud’s phenomenon 61 (88)
Renal crisis 3 (4)
Scleroderma 56 (81)
Telangiectasias NA
Tendon or bursal friction rubs 8 (12)
* Values are the number (percentage). NA  not available; DLCO 
carbon monoxide diffusing capacity; FVC  forced vital capacity;
ILD  interstitial lung disease.
† 80% predicted.
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have such broad geographic representation (14). Experts
involved in generating the candidate criteria were differ-
ent from those supplying patients (with the exception of 1
expert [TAM]), thereby reducing potential bias from circu-
larity of reasoning (21,23).
There are limitations to consider in the interpretation of
this study. One limitation to consider is missing data. This
is partially related to the fact that data were not collected
speciﬁcally for this study, but rather had been previously
collected for other purposes. As a result, not all sites
collect the same variables. To overcome this challenge, we
included multiple sites so that there were sufﬁcient data to
evaluate each candidate criterion. Not all sites categorized
the variable in the same manner in which the candidate
criteria have been proposed. This has introduced some
variability in comparisons across sites. However, the same
deﬁnition for each criterion was applied for within-site
comparisons. Furthermore, despite the variability in deﬁ-
nitions of items across sites, we were able to demonstrate
a moderate correlation between the empirical and expert
rankings. Many sites were academic medical centers; how-
ever, the CSRG and 1000 Faces of Lupus databases en-
roll patients from both academic and community sites,
so the generalizability to other nonacademic practices is
likely present (especially due to the fact that the ORs
were similar among the various databases used for this
study).
The ethnic background of the patients was not evaluated
in this study. There may be an overrepresentation of white
patients. Given variations in the frequency of speciﬁc
Table 6. Pooled ORs and ranking of candidate criteria*
Criterion
Pooled mean
OR (95% CrI)
Empirical
ranking
Expert-based
ranking
Renal crisis NE 1† 9
Digital pulp loss or acroosteolysis NE 1† 13‡
Scleroderma skin changes 426.7 (256.5–691.2) 2 1
Telangiectasias 91.4 (57.6–154.5) 3 11
Anti–RNA polymerase III antibody 75.4 (13.2–312.6) 4 6
Puffy ﬁngers 34.9 (24.0–49.2) 5 12
Finger ﬂexion contractures 29.0 (17.8–46.2) 6 19
Tendon or bursal friction rubs 26.81 (2.4–91.9) 7 10
Anti–topoisomerase I antibody 24.9 (12.7–48.0) 8 2
Raynaud’s phenomenon 24.1 (15.3–37.5) 9 7
Fingertip ulcers or pitting scars 19.3 (12.7–28.8) 10 5
Anticentromere antibody 13.8 (9.0–21.0) 11 3
Abnormal nailfold capillary pattern 10.4 (6.9–15.1) 12 4
Gastroesophageal reﬂux disease 7.6 (5.9–9.7) 13 17
Antinuclear antibody 6.06 (4.1–8.8) 14 13‡
Calcinosis 6.05 (3.4–10.5) 15 18
Dysphagia 5.7 (4.2–7.7) 16 19
Esophageal dilation 5.6 (2.9–10.2) 17 14
ILD or pulmonary ﬁbrosis 4.5 (3.4–5.8) 18 8
Anti–PM-Scl antibody 2.4 (1.9–7.1) 19 20‡
Pulmonary arterial hypertension 1.9 (1.4–2.4) 20 15
Reduced DLCO 1.5 (1.1–2.0) 21 16
Reduced FVC 0.9 (0.6–1.3) 22 20‡
* OR  odds ratio; 95% CrI  95% credible interval; NE  not estimated; ILD  interstitial lung disease;
DLCO  carbon monoxide diffusing capacity; FVC  forced vital capacity.
† Tied rankings. Renal crisis, digital pulp loss, and acroosteolysis did not occur in any mimicker patients;
therefore, ORs were not estimated. An inﬁnitely small numerical adjustment would result in an inﬁnitely
large OR.
‡ Tied rankings.
Figure 1. Scatter plot of the empirical-based ranking and the
expert-based ranking of the candidate items. The correlation be-
tween the 2 rankings was a Spearman’s rho of 0.53 (P  0.01).
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criteria (e.g., autoantibodies, lung disease) across ethnic
groups, this may affect the external validity of the devel-
oped criteria (31). In this study, there is some ethnic vari-
ation across the databases we used. The Pittsburgh cohort
includes African American patients (32); the 1000 Faces of
Lupus database includes Asian, First Nations, and African
American patients (33); and the Toronto cohort includes
African American and Asian (East Asian and Southeast
Asian) patients (30). Subsequent phases of criteria devel-
opment will need to consider the performance of classiﬁ-
cation criteria in different ethnic groups.
A potential limitation is that the investigators ascertain-
ing the criteria knew the diagnoses. Criteria were evalu-
ated based on local research protocols or the local standard
of care, and this may introduce veriﬁcation bias. Veriﬁca-
tion bias occurs when disease status is not determined in
all subjects who are evaluated for criteria and when the
probability of veriﬁcation depends on the criteria result
and/or other clinical variables. When veriﬁcation of dis-
ease status is more likely among patients with positive
criteria, a bias is introduced that can increase the sensitiv-
ity of the criteria and reduce its speciﬁcity (34). In our
study, the majority of SSc patients underwent evaluation
of all criteria (e.g., echocardiogram and pulmonary func-
tion tests). However, in the case of SSc comparator pa-
tients, evaluation of many of the criteria is not routinely
done in asymptomatic patients and even in symptomatic
patients; performing invasive tests such as right heart cath-
eterization or high-resolution computed tomography tho-
rax scans may not be done on mimickers as often as SSc
patients. Subsequent phases of criteria development may
need to consider design or analytic techniques to account
for veriﬁcation bias (34). It would not be likely that within
a database the investigators did not have a working deﬁ-
nition of the disease(s) studied, but the criteria used to
make the diagnosis may have been formal criteria or expert
opinion. Future prospective data collection that compares
patients with SSc and mimickers may reduce this bias
when cases are then reanalyzed by experts blinded to the
diagnosis.
Our study results provide sufﬁcient ﬁdelity to justify
proceeding with the next phase of criteria development,
which is prospective case and control ascertainment. Dur-
ing the next phase, the same deﬁnitions of items will be
applied to all patients and multiple sites will test each
item. Given the high discriminating ability of the items
using the non-SSc comparisons in this study (e.g., SLE),
the next phase of development should include non-SSc
comparisons that more closely resemble SSc, such as eo-
sinophilic fasciitis, generalized morphea, and nephrogenic
systemic ﬁbrosis. During the next phase, the scaling of the
criteria will need to be considered. The criteria could be
additive (e.g., SLE classiﬁcation criteria [35,36]), hierarchi-
cal (e.g., 1980 SSc classiﬁcation criteria [2,3]), or weighted
(e.g., rheumatoid arthritis classiﬁcation criteria [37]).
In conclusion, our study has demonstrated that the can-
didate SSc items have good face, discriminant, and con-
struct validity. These items should be tested in the next
phases of SSc classiﬁcation development.
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